Roivant reported that its inhaled drug candidate mosliciguat met mid-stage study goals, supporting its development plan for pulmonary hypertension and strengthening cash prospects for the company. In a 16-week Phase 2 study, Roivant said mosliciguat achieved a statistically significant 56% placebo-adjusted reduction in pulmonary vascular resistance. Roivant also reported statistically significant improvements across key secondary endpoints, including 35-meter improvement in six-minute walk distance and a 53% placebo-adjusted reduction in NT-proBNP. Separate coverage highlights the same Phase 2 update in interstitial lung disease, reinforcing the breadth of Roivant’s respiratory pipeline. The results matter commercially because mosliciguat is tied to a licensing origin from Bayer and could support additional label expansion opportunities if subsequent trials confirm benefit.